NMN and NR Legal & Patent Challenges: What the FDA Regulatory Field Means for You

Why NMN's Legal Status Changed Overnight in 2022

The FDA's November 2022 response to a citizen petition filed by Metro International Biotech, LLC marked the sharpest regulatory turn in NAD-precursor history. The agency determined that NMN meets the statutory definition of a drug under 21 U.S.C. § 321(ff)(3)(B)(ii), which bars a substance from dietary supplement classification if it was authorized for clinical investigation as a drug before it was marketed as a supplement.

The IND-First Rule and How It Applied to NMN

Metro filed Investigational New Drug application 149,036 for NMN before any dietary supplement manufacturer had submitted a new dietary ingredient (NDI) notification to the FDA. Under the Federal Food, Drug, and Cosmetic Act, that sequence matters enormously. Once a compound crosses the IND threshold first, it cannot later claim supplement status without an explicit act of Congress or a specific FDA exemption.

The FDA's November 2022 letter stated: "Based on the information available to FDA, we conclude that NMN is excluded from the dietary supplement definition." This is not a safety finding. It is a classification decision based solely on chronological regulatory sequence. [1]

What the Ruling Does Not Mean

The ruling does not mean NMN is dangerous. It does not make possession or personal use illegal. It means manufacturers cannot legally market NMN as a dietary supplement in the United States, and retailers who continue to do so risk FDA enforcement action including warning letters, injunctions, or product seizure.

Several companies received informal FDA warning signals within 12 months of the ruling. Products labeled "NMN dietary supplement" still appear on major e-commerce platforms as of mid-2025, representing an unresolved enforcement gap. [2]

NR's Regulatory Status: Still a Supplement, But Not Without Battles

Nicotinamide riboside occupies a different legal position. ChromaDex submitted an NDI notification for NR (sold under the trade name Tru Niagen) in 2015, and the FDA did not object. That notification predates any IND filing for NR as a standalone drug, placing it securely in the supplement category under current law.

ChromaDex's Patent Portfolio and Its Legal Consequences

ChromaDex holds more than 40 patents related to NR synthesis, formulation, and certain metabolic uses. These include U.S. Patent 8,197,807 (covering NR compositions) and patents acquired from the Dartmouth licensing portfolio developed by Charles Brenner's laboratory. [3]

Elysium Health, a competing supplement company, licensed ChromaDex's NR technology in 2014 and then terminated the agreement in 2016, leading to years of litigation. The dispute involved:

• Allegations that Elysium failed to pay licensing fees
• Elysium's counter-challenge to the validity of ChromaDex's patents before the Patent Trial and Appeal Board (PTAB)
• A 2020 jury verdict awarding ChromaDex approximately $45 million in damages

The PTAB proceedings were particularly significant because Elysium challenged whether NR compositions were truly novel and non-obvious given prior art in the B-vitamin literature. PTAB upheld the core ChromaDex patents. That outcome reinforced ChromaDex's market position but has not stopped generic NR from appearing in the supplement marketplace from manufacturers who argue they operate outside ChromaDex's patent claims. [4]

NR Labeling Requirements Under Current Rules

Because NR is classified as a dietary supplement, it must comply with 21 CFR Part 101 labeling requirements. These include:

• A Supplement Facts panel listing NR per serving
• No disease claims (e.g., "treats aging" is prohibited)
• Structure/function claims are permitted with a required disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."
• Manufacturer name and address on the label

ChromaDex's Tru Niagen also carries FDA-acknowledged GRAS (Generally Recognized as Safe) status for certain NR chloride formulations at doses up to 300 mg/day in food applications. [5]

The Patent War Over NMN: Metro International Biotech vs. The Market

Metro International Biotech, the company whose IND application triggered NMN's reclassification, holds composition-of-matter patents and method-of-treatment patents on NMN. Their strategy combined patent protection with regulatory exclusion, a dual barrier that effectively walls off the U.S. Dietary supplement market for NMN unless a competitor can either design around the patents or challenge them at PTAB.

Method-of-Treatment Claims and Their Scope

Metro's patents include claims covering the use of NMN to raise NAD+ levels in humans. Method-of-treatment patents are often narrower than composition patents but still restrict commercial application. A company selling NMN capsules for "NAD+ support" could be held to infringe a method claim even if the NMN molecule itself were somehow off-patent. [6]

International Patent Field

Outside the United States, patent coverage varies significantly. In the European Union, supplement regulation is governed by Directive 2002/46/EC, and NAD precursors have not faced the same IND-exclusion mechanism that applies in the U.S. NMN continues to be sold legally as a food supplement across most EU member states as of mid-2025, with no equivalent of the FDA's November 2022 exclusion ruling in place. Japan's regulatory agency, the PMDA, has not restricted NMN supplement sales either. [7]

This creates a fragmented global market where the same bottle that is legally sold in Tokyo or London cannot be lawfully marketed as a supplement in Chicago.

Clinical Evidence That Informs the Regulatory Debate

Regulatory classification decisions do not happen in isolation from science. The evidence base for NMN and NR has grown substantially since 2016, and that evidence feeds directly into FDA risk-benefit assessments and patent claim scope.

The Yoshino 2021 Trial: The Key Human NMN Study

Yoshino et al. (Science, 2021) conducted a randomized, placebo-controlled, double-blind trial of oral NMN in 25 postmenopausal women with prediabetes or overweight. Participants received 250 mg/day of NMN orally for 10 weeks. The study found that NMN increased skeletal muscle insulin signaling, specifically upregulating expression of genes involved in muscle remodeling and insulin sensitivity, compared with placebo. No serious adverse events were reported. [8]

That trial (N=25) is small by drug-approval standards. Reaching the safety database required for an NDA typically demands thousands of patient-years of exposure. The Yoshino study demonstrated biological activity but does not constitute sufficient evidence for drug approval on its own.

Trammell et al. 2016: NR Safety at 1,000 mg/Day

Trammell SA et al. Published a randomized, double-blind, crossover study of NR in healthy adults, showing that a single oral dose of 1,000 mg raised whole-blood NAD+ metabolites significantly above baseline without serious adverse events over an 8-week observation window. [9] This study formed part of the scientific basis for ChromaDex's GRAS submissions and NDI notification.

Liao et al. 2021: NMN in Older Adults

A 12-week trial of NMN at 250 mg/day in healthy older men (N=42) published in Nature Aging reported significant increases in NAD+ concentrations in blood, along with improvements in gait speed and grip strength compared with placebo. [10] The authors noted that effect sizes were modest and that longer trials with larger samples are needed before clinical recommendations can be made.

The table below summarizes the key trials that have directly influenced regulatory and patent arguments.

| Study | N | Dose | Duration | Key Finding | |---|---|---|---|---| | Yoshino et al. 2021 [8] | 25 | 250 mg/day NMN | 10 weeks | Improved skeletal muscle insulin signaling | | Trammell et al. 2016 [9] | 12 | 1,000 mg single dose NR | 8 weeks crossover | NAD+ elevation, no serious AEs | | Liao et al. 2021 [10] | 42 | 250 mg/day NMN | 12 weeks | Increased NAD+, improved gait and grip |

FDA Safety Signals and Post-Market Surveillance

Neither NMN nor NR has a completed Phase III trial. The FDA's MedWatch adverse event reporting system (FAERS) contains scattered reports for products labeled as NAD precursors, but the signal-to-noise ratio is low because many products combine NMN or NR with resveratrol, pterostilbene, or other compounds, making attribution difficult. [11]

Known Adverse Effects in Trial Data

Across the published human trials, the most commonly reported side effects were:

• Mild nausea (3 to 8% of participants across multiple NR studies)
• Flushing, less common than with nicotinic acid (niacin) but documented
• Mild headache in the first week of supplementation

No hepatotoxicity signals have been identified in controlled trials. Doses studied in humans range from 100 mg/day to 2,000 mg/day for NR and 100 mg/day to 1,200 mg/day for NMN. [12]

The FDA's Ongoing Comment Process

After the November 2022 NMN exclusion, the FDA opened a public comment period that closed in March 2023. The agency received comments from industry groups including the Natural Products Association, which argued that the NMN exclusion was inconsistent with prior agency practice and harmful to consumers who rely on the supplement. The FDA has not issued a final rule as of mid-2025, leaving the market in a state of regulatory ambiguity. [1]

What the NMN Exclusion Means for Prescribers and Patients

For clinicians, the practical implications divide into three categories.

Prescribing and Recommending NMN

Physicians can discuss NMN with patients as an investigational compound. They cannot legally recommend that patients purchase NMN products labeled as dietary supplements, because those products are in violation of FDA guidance. Compounding pharmacies operating under Section 503A or 503B of the FD&C Act occupy a gray zone: FDA has not explicitly prohibited compounded NMN preparations for individual patients, but no compounded NMN formulation has been reviewed for safety and efficacy. [13]

Advising Patients Who Already Use NMN

Patients who ask about NMN they bought before the ruling, or products still being sold online, should be told that the regulatory status does not by itself indicate toxicity. The available human trial data suggest NMN at doses of 250 to 500 mg/day is well tolerated over periods of 10 to 12 weeks. Longer-term safety data simply do not yet exist in published form. Patients with hepatic impairment, those on PARP inhibitors (which compete for NAD+ substrate), or those taking niacin-based lipid therapies should consult their prescriber before adding any NAD precursor. [8]

NR as the Legally Available Alternative

Patients seeking an NAD precursor through legal channels in the U.S. Can access NR-based supplements. ChromaDex's Tru Niagen is the most rigorously documented formulation, with human trial data supporting doses of 300 mg to 1,000 mg/day for NAD+ elevation. Physicians recommending NR should note that no NR product has FDA drug approval and that structure/function claims on labels are not the same as clinically validated indications. [5]

Enforcement Actions and Industry Response

The FDA's Office of Dietary Supplement Programs has not yet issued a public warning letter specifically naming an NMN supplement manufacturer as of mid-2025. This enforcement lag is common after classification rulings; the agency typically prioritizes products with documented safety signals over classification-only violations.

Industry response has been mixed. Some companies reformulated products to remove NMN and substitute NR or NMN precursors such as nicotinamide (NAM) or niacinamide, which are not subject to the IND-exclusion rule. Others simply relabeled NMN products as "research chemicals" or "for laboratory use only" to sidestep the dietary supplement definition, a maneuver that creates its own compliance risks under FDA's structure/function claim rules. [14]

The Council for Responsible Nutrition (CRN) has publicly called on the FDA to clarify its enforcement intentions and to issue a final rule, arguing that prolonged ambiguity harms legitimate manufacturers and confuses consumers. [15]

Pathway Forward: How NMN Could Return to Legal Supplement Status

Three routes exist for NMN to regain legal dietary supplement status.

Congressional action is the broadest route. A bill explicitly amending 21 U.S.C. § 321(ff)(3)(B)(ii) to exempt NMN, or any NAD precursor with a pre-existing safety record, would override the FDA's classification. No such bill has passed as of mid-2025, though draft language has been circulated in industry lobbying documents.

A successful GRAS petition, demonstrating that NMN is generally recognized as safe by qualified experts based on published scientific evidence, could support an argument for different regulatory treatment. GRAS status is distinct from supplement classification but can influence the agency's regulatory calculus.

Metro International Biotech itself could withdraw or abandon the relevant IND, removing the predicate that triggered the exclusion. Whether the company has any commercial incentive to do so depends on whether it intends to pursue NDA approval. No NDA filing for NMN had been publicly registered with the FDA as of the date of this article's last review.